Related references
Note: Only part of the references are listed.Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience
S. Dighe et al.
COLORECTAL DISEASE (2012)
Immunostaining for mismatch repair (MMR) protein expression in colorectal cancer is better and easier to interpret when performed on diagnostic biopsies
Wakkas Fadhil et al.
HISTOPATHOLOGY (2012)
Partial Pathologic Response and Nodal Status as Most Significant Prognostic Factors for Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy
Marianne Huebner et al.
WORLD JOURNAL OF SURGERY (2012)
Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma: How Reliable are Biopsy Samples?
Jinru Shia et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Molecular Genetics of Colorectal Cancer
Eric R. Fearon
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors
Teodora Evgenieva Goranova et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer
A. S. Dhadda et al.
EUROPEAN JOURNAL OF CANCER (2011)
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Filip Janku et al.
PLOS ONE (2011)
KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Microsatellite Instability Detection by High-Resolution Melting Analysis
Ramunas Janavicius et al.
CLINICAL CHEMISTRY (2010)
Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection
Salih Ibrahem et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue
Wakkas Fadhil et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Accumulation of driver and passenger mutations during tumor progression
Ivana Bozic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
A. Oden-Gangloff et al.
BRITISH JOURNAL OF CANCER (2009)
High-Resolution DNA Melting Analysis: Advancements and Limitations
Carl T. Wittwer
HUMAN MUTATION (2009)
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The putative tumour modifier gene ATP5A1 is not mutated in human colorectal cancer cell lines but expression levels correlate with TP53 mutations and chromosomal instability
R. Seth et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
Paloma Cejas et al.
PLOS ONE (2009)
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Jihye Yun et al.
SCIENCE (2009)
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Daniele Santini et al.
ONCOLOGIST (2008)
Comparative lesion sequencing provides insights into tumor evolution
Sian Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma
B Baisse et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer
W Giaretti et al.
ANALYTICAL CELLULAR PATHOLOGY (2000)